Imunon Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
IMNN Nasdaq 8731 https://imunon.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Imunon Inc

IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101 - Apr 18th, 2024 12:30 pm
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine… - Apr 12th, 2024 10:41 am
IMUNON Reports Compliance with Nasdaq Listing Requirements - Apr 11th, 2024 12:00 pm
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript - Apr 1st, 2024 11:08 pm
IMUNON Reports 2023 Financial Results and Provides Business Update - Mar 28th, 2024 12:00 pm
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses - Mar 25th, 2024 12:30 pm
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 - Mar 21st, 2024 9:00 pm
IMUNON Files IND Application to Begin Human Testing of IMNN-101 - Mar 13th, 2024 12:00 pm
IMUNON Announces Leadership Change - Mar 12th, 2024 9:00 pm
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 - Feb 29th, 2024 1:30 pm
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer - Feb 27th, 2024 1:30 pm
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine - Feb 22nd, 2024 1:00 pm
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 11th, 2023 1:30 pm
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript - Nov 20th, 2023 11:45 pm
IMNN: Promising Interim PFS and OS Data for IMNN-001 in OVATION 2 Trial… - Nov 17th, 2023 2:11 pm
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023 - Nov 14th, 2023 2:00 pm
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update - Nov 14th, 2023 1:00 pm
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023 - Nov 7th, 2023 1:30 pm
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress - Oct 23rd, 2023 12:30 pm
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations - Oct 19th, 2023 12:30 pm